PolyNovo Biomaterials Pty Ltd Next Generation Biodegradeable Polymers
NovoSorbTM was originally invented and developed by CSIRO scientists. A large multi-disciplined team from the CSIRO's polymer chemistry, polymer processing and biological disciplines worked for approximately 5 years to establish the NovoSorbTM technology. The majority of the polymer design work was directed by PolyNovo's principle scientists Drs Gunatillake and Adhikari.
In July 2004 Xceed biotechnology invested $5.1 million into PolyNovo for 50% of the equity in the newly formed company. The initial investment provided operational funds to set-up the company and start applied device development, manufacturing set-up and safety studies.
In January 2006 as part of the transaction with Medtronic Vascular, Xceed invested a further $3 million, taking Xceed's ownership position to 60%. In June 2006 PolyNovo formed its first joint venture company with Dr John Greenwood (NovoSkinTM) to develop innovative products in wounds management.
Main business focus/
Listing by sector:
- Medical Devices - Biomaterials
PolyNovo actively collaborates with CSIRO on multiple fronts.
Currently we have joint teams working on:
Through Dr John Greenwood and NovoSkinTM we collaborate with the Royal Adelaide Hospital Skin Engineering laboratories and CSIRO.
- Biodegradable Temporizing Matrix
- Easy Application Synthetic Epidermis (EASE)
Bionic Technologies Australia is a collaboration that is funded through an STI grant. Our partners are The Bionic Ear Institute, St Vincents Hospital, CSIRO and University of Wollongong.
- Nerve Repair Conduits
- Inner Ear Infection Control
PolyNovo currently has a collaborative research program with Monash University’s Immunology and Stem Cell Laboratories.
- NovoSorbTM Stem Cell Applications
|Contact person||Mr Laurent Fossaert|
|Job Title||Chief Executive Officer|
|Address||2/320 Lorimer Street|
|Phone||+61 (0) 3 8681 4050|
|Fax||+61 (0) 3 8681 4099|